AMN Healthcare reported mixed Q3 2025 results, with adjusted EPS of 39 cents and revenues of $634.5 million both exceeding analyst estimates, despite year-over-year declines of 36.1% and 7.7% respectively, leading to an 8.5% pre-market stock gain. The company experienced significant margin contraction and revenue declines across all segments, but provided Q4 2025 revenue guidance of $715-$730 million, which, while a year-over-year decline, significantly surpasses the Zacks Consensus Estimate, driven by anticipated strong sequential growth in travel nursing.
AMN Healthcare reported Q3 2025 adjusted EPS of $0.39 and revenues of $634.5 million, both exceeding consensus estimates despite year-over-year declines of 36.1% and 7.7% respectively. This beat prompted an 8.5% gain in pre-market trading, signaling a positive market reaction to the better-than-expected results. However, the company experienced significant margin pressure, with gross margin contracting 193 basis points to 29.1% and adjusted operating margin declining 200 basis points to 7.2%. All three segments recorded year-over-year revenue declines, including a 20% drop in travel nurse staffing and a 32% decrease in vendor management systems, partially offset by growth in Allied and Locum tenens revenues. For Q4 2025, AMN projects revenues of $715-$730 million, a 1-3% year-over-year decline but notably above the Zacks Consensus Estimate of $613.4 million. Management anticipates strong sequential volume growth for travel nursing, driven by a rebound in staffing orders and higher winter demand, which appears to be underpinning the positive outlook despite the current Zacks Rank #5 (Strong Sell).
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
